Switching from branded to generic glatiramer acetate: two-year clinical data from the GATE trial further support the continued efficacy and tolerability of generic glatiramer acetate

被引：0
|
作者：
Cohen, J. A. [1 ]
Belova, A. [2 ]
Barkhof, F. [3 ]
Wolf, C. [4 ]
van den Tweel, E. R. W. [5 ]
Oberye, J. J. L. [5 ]
Mulder, R. [5 ]
Koper, N. P. [5 ]
Selmaj, K. [6 ]
机构：
[1] Cleveland Clin, Mellen Ctr, Cleveland, OH 44106 USA
[2] Res Inst Traumatol & Othopaedy, Funct Diagnost, Nizhnii Novgorod, Russia
[3] Vrije Univ Amsterdam Med Ctr, Radiol, Amsterdam, Netherlands
[4] Lycalis Sprl, Brussels, Belgium
[5] Synthon BV, Nijmegen, Netherlands
[6] Med Univ Lodz, Lodz, Poland
来源：
MULTIPLE SCLEROSIS JOURNAL | 2015年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1050
引用
收藏
页码：536 / 537
页数：2
相关论文
共 40 条
  • [21] Efficacy and safety of generic glatiramer acetate Timexon® : results of the 12-month extension of BCD-063-1 international double-blind randomized placebo-controlled clinical study of efficacy and safety of Timexon® in comparison with Copaxone®
    Boyko, A.
    Zakharova, M.
    Kotov, S.
    Khabirov, F.
    Sazonov, D.
    Trinitatsky, Y.
    Zinkina-Orikhan, A.
    Tursunova, C.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 340 - 340
  • [22] A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial
    Ziemssen, Tjalf
    Bajenaru, Ovidiu A.
    Carra, Adriana
    de Klippel, Nina
    de Sa, Joao C.
    Edland, Astrid
    Frederiksen, Jette L.
    Heinzlef, Olivier
    Karageorgiou, Klimentini E.
    Lander Delgado, Rafael H.
    Landtblom, Anne-Marie
    Macias Islas, Miguel A.
    Tubridy, Niall
    Gilgun-Sherki, Yossi
    JOURNAL OF NEUROLOGY, 2014, 261 (11) : 2101 - 2111
  • [23] A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial
    Tjalf Ziemssen
    Ovidiu A. Bajenaru
    Adriana Carrá
    Nina de Klippel
    João C. de Sá
    Astrid Edland
    Jette L. Frederiksen
    Olivier Heinzlef
    Klimentini E. Karageorgiou
    Rafael H. Lander Delgado
    Anne-Marie Landtblom
    Miguel A. Macías Islas
    Niall Tubridy
    Yossi Gilgun-Sherki
    Journal of Neurology, 2014, 261 : 2101 - 2111
  • [24] Efficacy of Delayed-Release Dimethyl Fumarate in Newly Diagnosed and Other Early Multiple Sclerosis Patients, and Patients Switching from Interferon or Glatiramer Acetate, in Routine Medical Practice: Interim Results from ESTEEM
    Giles, Kathryn
    Hanna, Jerome
    Wu, Fan
    Taylor, Catherine
    Balashov, Konstantin
    Macdonell, Richard
    Windsheimer, Joerg
    Everage, Nicholas
    NEUROLOGY, 2018, 90
  • [25] Effectiveness of Delayed-release Dimethyl Fumarate on Clinical and Patient-reported Outcomes in Patients With Relapsing Multiple Sclerosis Switching From Glatiramer Acetate: RESPOND, a Prospective Observational Study
    Kresa-Reahl, Kiren
    Repovic, Pavle
    Robertson, Derrick
    Okwuokenye, Macaulay
    Meltzer, Leslie
    Mendoza, Jason P.
    CLINICAL THERAPEUTICS, 2018, 40 (12) : 2077 - 2087
  • [26] Erratum to: A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial
    Tjalf Ziemssen
    Ovidiu A. Bajenaru
    Adriana Carrá
    Nina de Klippel
    João Correia de Sá
    Astrid Edland
    Jette L. Frederiksen
    Olivier Heinzlef
    Klimentini E. Karageorgiou
    Rafael H. Lander Delgado
    Anne-Marie Landtblom
    Miguel A. Macías Islas
    Niall Tubridy
    Yossi Gilgun-Sherki
    Journal of Neurology, 2015, 262 : 248 - 248
  • [27] Two studies in one: A propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL
    Alsop, Jonathan
    Medin, Jennie
    Cornelissen, Christian
    Vormfelde, Stefan Viktor
    Ziemssen, Tjalf
    PLOS ONE, 2017, 12 (05):
  • [28] A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial (vol 261, pg 2101, 2014)
    Ziemssen, Tjalf
    Bajenaru, Ovidiu A.
    Carra, Adriana
    de Klippel, Nina
    de Sa, Joao Correia
    Edland, Astrid
    Frederiksen, Jette L.
    Heinzlef, Olivier
    Karageorgiou, Klimentini E.
    Delgado, Rafael H. Lander
    Landtblom, Anne-Marie
    Macias Islas, Miguel A.
    Tubridy, Niall
    Gilgun-Sherki, Yossi
    JOURNAL OF NEUROLOGY, 2015, 262 (01) : 248 - 248
  • [29] Effectiveness of Delayed-release Dimethyl Fumarate on Clinical and Patient-reported Outcomes in Patients With Relapsing Multiple Sclerosis Switching From Glatiramer Acetate: RESPOND, a Prospective Observational Study (vol 40, pg 2077, 2018)
    Kresa-Reahl, Kiren
    Repovic, Pavle
    Robertson, Derrick
    Okwuokenye, Macaulay
    Meltzer, Leslie
    Mendoza, Jason P.
    CLINICAL THERAPEUTICS, 2019, 41 (12) : 2662 - 2662
  • [30] Two-year analysis of efficacy and safety data from Black and Hispanic people with relapsing multiple sclerosis receiving ocrelizumab treatment in the CHIMES trial
    Monson, Nancy L.
    Wu, Gregory
    Cuascut, Fernando
    Amezcua, Lilyana
    Williams, Mitzi Joi
    Bernitsas, Evanthia
    Reder, Anthony
    Hooker, Juzar
    Sokhi, Dilraj Singh
    Nourbakhsh, Bardia
    Obeidat, Ahmed Z.
    Harp, Christopher
    Pei, Jinglan
    Abioye, Ibraheem
    Vartanian, Timothy
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 617 - 618
1234